Pediatric intestinal retransplantation: Techniques, management, and outcomes

Transplantation

Volumn 86, Issue 12, 2008, Pages 1777-1782

  Mazariegos, George V ^a   Soltys, Kyle ^a   Bond, Geoffrey ^a   Girnita, Alin ^a   MacHaidze, Zurab ^a   Jaffe, Ronald ^a   Green, Michael ^a   Martin, Dolly ^a   Zeevi, Adriana ^a   Squires, Robert ^a   Perez, Graciela ^a   Abu Elmagd, Kareem ^a   Sindhi, Rakesh ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Chronic rejection; Intestine retransplantation; Outcomes; Pediatric

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; INFUSION FLUID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ANEURYSM; ARTICLE; BLEEDING; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DISEASE SEVERITY; FALSE ANEURYSM; FATALITY; FOLLOW UP; FUNGEMIA; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; KIDNEY; LIVER; LIVER FAILURE; LYMPHOPROLIFERATIVE DISEASE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETRANSPLANTATION; SCHOOL CHILD; SURVIVAL TIME; TOTAL PARENTERAL NUTRITION; CLASSIFICATION; IMMUNOLOGY; INTESTINE; METHODOLOGY; MORTALITY; POSTOPERATIVE COMPLICATION; REOPERATION; STATISTICS; SURVIVAL RATE; TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; HUMANS; INTESTINES; POSTOPERATIVE COMPLICATIONS; REOPERATION; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58849164065     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181910f51     Document Type: Article

References (20)

1. Abu-Elmagd KM. Intestinal transplantation for short bowel syndrome and gastrointestinal failure: Current consensus, rewarding outcomes, and practical guidelines. J Gastroenterol 2006; 130(2 suppl 1): S132.
2. Fishbein TM, Matsumoto CS. Intestinal replacement therapy: Timing and indications for referral of patients to an intestinal rehabilitation and transplant program. J Gastroenterol 2006; 130(2 suppl 1): S147.
3. Kaufman SS, Atkinson JB, Bianchi A, et al., Indications for pediatric intestinal transplantation: A position paper of the American Society of Transplantation. Pediatr Transplant 2001; 5: 80.
4. Freeman RB Jr, Steffick DE, Guidinger MK, et al. Liver and intestine transplantation in the United States, 1997-2006.Am J Transplant 2008; 8(4 Pt 2): 958.
5. Magee JC, Krishnan SM, Benfield MR, et al. Pediatric transplantation in the United States, 1997-2006. Am J Transplant 2008; 8(4 Pt 2): 935.
6. Bond GJ, Mazariegos GV, Sindhi R, et al. Evolutionary experience with immunosuppression in pediatric intestinal transplantation. J Pediatr Surg 2005; 40: 274; discussion 279.
7. Reyes J, Mazariegos GV, Abu-Elmagd KM, et al., Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005; 5: 1430.
8. Noguchi Si S, Reyes J, Mazariegos GV, et al. Pediatric intestinal transplantation: The resected allograft. Pediatr Dev Pathol 2002; 5: 3.
9. Parizhskaya M, Redondo C, Demetris A, et al. Chronic rejection of small bowel grafts: Pediatric and adult study of risk factors and morphologic progression. Pediatr Dev Pathol 2003; 6: 240.
10. Grant D, Abu-Elmagd KM, Reyes J, et al. 2003 report of the intestine transplant registry: A new era has dawned. Ann Surg 2005; 241: 607.
11. Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States, 1996-2005.Am J Transplant 2007; 7(5 Pt 2): 1424.
12. Rose C, Green M, Webber S, et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol 2002; 40: 2533.
13. Green M, Reyes J, Webber S, et al. The role of antiviral and immuno-globulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97.
14. Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: The taboo concept. Lancet 1996; 348: 850.
15. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335.
16. Montgomery RA, Hardy MA, Jordan SC,etal. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181.
17. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
18. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels ofdonor specific alloantibody. Am J Transplant 2006; 6:346.
19. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
20. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.